| Human HLA-G Tetramer Protein (LTP10673) |
| LTP10673 |
| 100ug |
|
$1350 In stock |
| HLA-G is a molecule that was first known to confer protection to the fetus from destruction by the immune system of its mother, thus critically contributing to fetal-maternal tolerance. The first functional finding constituted the basis for HLA-G research and can be summarized as such: HLA-G, membrane-bound or soluble, strongly binds its inhibitory receptors on immune cells (NK, T, B, monocytes/dendritic cells), inhibits the functions of these effectors, and so induces immune inhibition. |
| Recombinant Human HLA-G Tetramer Protein is expressed from Expi293 with His tag and Avi tag at the C-terminal,tetramer is assembled by biotinylated monomer and streptavidin. It contains Gly25-Thr305(HLA-G),Ile21-Met119(B2M) and RIIPRHLQL peptide. |
| HLA-G Tetramer |
| Human |
| P17693-1(HLA-G)&P61769(B2M)&RIIPRHLQL |
| Gly25-Thr305(HLA-G),Ile21-Met119(B2M)and RIIPRHLQL peptide |
| The protein has a predicted MW of 258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on the Tris-Bis PAGE result. |
| Immobilized Human HLA-G Tetramer, His Tag at 0.5ug/ml (100ul/well) on the plate. Dose response curve for Anti-HLA-G Antibody, hFc Tag with the EC50 of 9.3ng/ml determined by ELISA (QC Test). The affinity constant of 4.62 nM as determined in SPR assay (Biacore T200). See testing image for detail. |
| C-His-Avi |
| Expi293 |
| > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
| Less than 1EU per ug by the LAL method. |
| Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 5% trehalose is added as a protectant before lyophilization. |
| Reconstituted protein stable at -80 C for 12 months, 4 C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
| Shipped at ambient temperature. |
| Centrifuge tubes before opening. Reconstituting to a concentration of more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| |